பைரன் அமின் ஜெஃப்பெரிஸ் News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from பைரன் அமின் ஜெஃப்பெரிஸ். Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In பைரன் அமின் ஜெஃப்பெரிஸ் Today - Breaking & Trending Today

Cellectis SA (CLLS) Q4 2020 Earnings Call Transcript

Cellectis SA (CLLS) Q4 2020 Earnings Call Transcript
Motley Fool Transcribers
© The Motley Fool
Logo of jester cap with thought bubble.
Cellectis SA (NASDAQ: CLLS)
Operator
Greetings. Welcome to the Cellectis Fourth Quarter and Full-Year 2020 Earnings Call. At this time, all participants are in a listen-only mode and a question-and-answer session will follow the formal presentation. [Operator Instructions] Please note this conference is being recorded.
At this time, I ll turn the conference over to Simon Harnest, Chief Investment Officer. Simon, you may begin.
This article is a transcript of this conference call produced for The Motley Fool. While we strive for our Foolish Best, there may be errors, omissions, or inaccuracies in this transcript. As with all our articles, The Motley Fool does not assume any responsibility for your use of this content, and we strongly encourage you to do your own research, including listening to ....

France General , North Carolina , United States , Andre Choulika , Hartaj Singh , Jack Allen , Hartaj Singh Oppenheimer , Wangzhi Li , Gena Wang , Salveen Richter Goldman Sachs , Soumit Roy Jones , Soumit Roy , Ingrid Bensinger , Gena Wang Barclays , Salveen Richter , Yigal Nochomovitz , Ingrid Bensinger Kempen , Nick Abbott , Yigal Nochomovitz Citigroup , Simon Harnest , Wangzhi Li Ladenburg , Samantha Corwin William Blair , Carrie Brownstein , Michael Schmidt Guggenheim , Jean Pierre Garnier , Biren Amin ,

GlycoMimetics Inc (GLYC) Q4 2020 Earnings Call Transcript

[Operator Instructions]
I would now like to turn the call over to Shari Annes of the Investor Relations group at GlycoMimetics. Please go ahead.
Shari Annes
Thank you. Good morning.
Today, we will review our accomplishments and financial results for both the three and 12-month periods ended December 31, 2020. We ll also update you on recent [Indecipherable]. The press release we issued this morning is available on the company s website at www.glycomimetics.com, under the Investors tab.
This call is being recorded. A dial-in phone replay will be available for 24 hours after the close of the call. The webcast replay will also be available on the Investor Relations section of the company s website for 30 days. ....

Shari Annes , Rachel King , Stephen Willey , Stephen Willey Stifel , Myra Rosario Herrle , Rachelk King , Zegbeh Jallah , Ericj Feldman , Helen Thackray , Biren Amin , Brian Hahn , John Magnani , Biren Amin Jefferies , Eric Feldman , Our Co , Regulatory Affairs , Md Anderson Cancer Center , Glycomimetics Inc , Department Of Leukemia , Duke University , Clinical Development , Society Of Hematologic Oncology , Investor Relations , Chief Executive Officer , Chief Financial , Chief Scientific Officer ,

Fate Therapeutics Inc (FATE) Q4 2020 Earnings Call Transcript

Operator
Welcome to the Fate Therapeutics Fourth Quarter 2020 Financial Results Conference Call. At this time, all participants are in a listen-only mode. This call is being webcast live on the Investors and Media section on Fate s website at fatetherapeutics.com. As a reminder, today s call is being recorded.
I would now like to introduce Scott Wolchko, President and CEO of Fate Therapeutics. The floor is yours.
Scott Wolchko
President and Chief Executive Officer
Thank you. Good afternoon, and thanks everyone for joining us for the Fate Therapeutics fourth quarter 2020 financial results call. Shortly after 4:00 P.M. Eastern Time today, we issued a press release with these results, which can be found on the Investor section of our website under Press Releases. In addition, our Form 10-K for the year ended December 31, 2020 was filed shortly thereafter and can be found on the Investor section of our website under Financial Information. ....

United States , Robyn Karnauskas , Matt Biegler , Alethia Young Cantor , Alethia Young , Michel Sadelain , Wayne Chu , Peter Lawson , Matt Biegler Oppenheimer , Yigal Nochomovitz , Nick Abbott , Ibanez Ventoso , Mara Goldstein , Ben Burnett , Scott Wolchko , Mara Goldstein Mizuho , Bob Valamehr , Sloan Kettering , Ed Dulac , Michael Schmidt Guggenheim , Srikripa Devarakonda Truist , Biren Amin , Biren Amin Jefferies , Michael Schmidt , Peter Lawson Barclays , Ibanez Ventoso Stifel ,

Neurocrine Biosciences Inc (NBIX) Q4 2020 Earnings Call Transcript

Operator
Good day, everyone, and welcome to today s Neurocrine Biosciences Reports Fourth Quarter and Year-End 2020 Results. [Operator Instructions] [Operator Instructions]
It is now my pleasure to turn the conference over to Vice President of Investor Relations, Todd Tushla.
Todd Tushla
Vice President of Investor Relations
Thank you, Clorey. Good afternoon, everyone, and thank you for joining us on our fourth quarter and full year 2020 earnings call. On the call today is Kevin Gorman, our Chief Executive Officer; Matt Abernethy, our Chief Financial Officer; Eiry Roberts, our Chief Medical Officer; Eric Benevich, our Chief Commercial Officer; and Kyle Gano, our Chief Business Development and Strategy Officer. ....

United States , South Korea , Todd Tushla , Anupam Rama , Josh Schimmer Evercore , Kevinc Gorman , Eiryw Roberts , Paul Matteis Stifel , Kyle Gano , Tanabe Pharma , Paul Matteis , Matt Abernethy , Josh Schimmer , Kylew Gano , Laura Christianson Cowen , Paul Choi Goldman Sachs , Brian Skorney , Eiry Roberts , Laura Christianson , Matthewc Abernethy , Biren Amin , Paul Choi , Tazeen Ahmad , Biren Amin Jefferies , Brian Skorney Baird , Kevin Gorman ,